Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on longevity research and SIRT6-based gene therapies. This news page aggregates regulatory announcements and corporate updates related to Genflow’s scientific programs, intellectual property, and capital markets activity.
Readers can follow developments in Genflow’s gene therapy pipeline, including its 12‑month proof‑of‑concept clinical trial in aged dogs that evaluates a SIRT6‑centenarian gene therapy for age‑related decline. Company updates have highlighted dosing milestones, safety and tolerability observations in elderly dogs, and the design of blinded clinical assessments using biomarkers linked to sarcopenia, healthspan, and lifespan.
The news flow also covers Genflow’s plans to explore GF‑1002 in MASH (Metabolic Dysfunction‑Associated Steatohepatitis), reflecting its interest in metabolic and age‑related disorders. In addition, announcements detail progress in the company’s intellectual property strategy, such as European Patent Office publications recognizing the patentability of SIRT6 variant claims and the publication of a second European patent application titled “SIRT6 Variant for NASH.”
Investors and observers will also find information on equity issues, warrants, and voting rights, including share subscriptions, warrant terms, and total issued share capital figures disclosed for regulatory purposes. Notifications of major holdings and participation in sector events, such as the J.P. Morgan Healthcare Conference, appear in the same stream.
By reviewing the GENFF news page, users can see how Genflow communicates the evolution of its SIRT6 gene therapy platform, its animal health and human-focused programs, and its ongoing regulatory and capital markets disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as of 31 March 2026. The company has 535,653,205 ordinary shares of £0.0003 each, with none held in treasury, so total voting rights equal 535,653,205.
Shareholders may use this figure as the denominator for FCA Disclosure Guidance and Transparency Rules notifications regarding changes in shareholding.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) raised £800,000 by issuing 42,105,263 new ordinary shares at 1.9p each, with one warrant per subscription share exercisable at the same price for two years. Admission of the new shares is expected around 11 March 2026.
The net proceeds are intended to fund scientific programs, extend cash runway and support potential licensing negotiations; CEO Eric Leire and chairman Gad Berdugo participated in the Subscription.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that all resolutions at its General Meeting on March 2, 2026 were duly passed by shareholders. Proxy voting showed strong support for both the directors' authority to allot securities and the disapplication of pre-emption rights.
The company reported vote totals and percentages for each resolution, with over 97% of votes cast in favour on both items and detailed proxy counts provided.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) confirmed receipt of the first instalment of a €4.0 million non-dilutive grant from the Wallonia Region.
The company received €336,467 on March 2, 2026, for a three-year development programme supporting GF-1002 in MASH, with further instalments tied to milestone-based disbursements and applied to eligible project activities.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) reports positive preliminary interim results from the SLAB trial testing its SIRT6 gene therapy in aged beagles. The randomised, blinded study enrolled 24 dogs aged >10 years across four groups. During the dosing period, all treated cohorts showed superior survival, functional gains and a favourable safety profile versus control. Key mechanistic endpoints—methylation clock and muscle histology—remain under analysis, with a comprehensive update expected within approximately two months.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) has called a General Meeting for 11:00 on 2 March 2026 to seek shareholder authority to issue up to 188,947,368 new ordinary shares (~38% of current issued share capital) to enable a potential equity raise.
The raise would be by private placement, may include warrants, and proceeds are intended for IND-enabling work on MASH, an aged-beagle trial payment, glaucoma PoC studies, business development, and patent work.
Genflow Biosciences (OTC:GENFF) major-holdings notice: Jonathan Mark Swann crossed a regulatory threshold, increasing his direct voting stake to 12.13% of voting rights (59,861,278 votes) on 23-Jan-2026. The issuer notified the market on 25-Jan-2026 and the completion date is listed as 24-Jan-2026.
The filing shows a prior position of 11.32% (55,861,278 votes), no voting rights via financial instruments, and no additional information disclosed.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received administrative approval for approximately €4 million in non-dilutive funding from the Wallonia Region to support GF-1002 development for MASH.
First instalment expected no later than May 2026; support covers a three-year programme and makes 2026 priorities capital-efficient, with multiple programme readouts planned.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) appointed Gad Berdugo as Independent Non-Executive Chairman effective immediately, while Tamara Joseph remains on the board to preserve continuity and governance. Mr. Berdugo brings over 30 years of leadership across biotech corporate development, U.S. capital markets and RNA-LNP therapeutics, and currently leads Explorium Capital LLC. The company said his expertise will support advancement of gene-therapy programs, evaluation of delivery technologies, and expanded U.S. engagement. Management highlighted key data readouts expected in 2026. The announcement notes Mr. Berdugo does not own any Genflow shares.
Genflow (OTCQB:GENFF) reported completion of the dosing phase in its blinded canine trial of a SIRT6-based gene therapy on December 16, 2025. All enrolled dogs received full dosing and no adverse events were reported during administration.
Genflow expects a first efficacy read in mid-to-late January 2026 (blood analyses and muscle biopsies) and a second efficacy assessment at the six-month (180-day) timepoint with results expected in June–July 2026. The company plans to resume licensing discussions after efficacy analysis.